查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球胆固醇检测产品市场 - 2023-2030年
市场调查报告书
商品编码
1297771

全球胆固醇检测产品市场 - 2023-2030年

Global Cholesterol Testing Products Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球胆固醇检测产品的市场规模在2022年达到85亿美元，预计到2030年将见证有利可图的增长，达到159亿美元。在2023-2030年的预测期间，该市场的年复合增长率为8.3%。

胆固醇检测产品是用于测量和监测血液中胆固醇水平的医疗设备、检测试剂盒、试剂和消耗品。血液中的高胆固醇水平会增加心血管疾病的风险，如心脏病发作和中风。医疗保健提供者使用这些产品来测量和监测心血管疾病患者或有风险的患者的胆固醇水平。

胆固醇检测产品的市场是由人们对与高胆固醇水平相关的健康风险，如心血管疾病、中风和糖尿病的认识不断提高所推动的。这导致医疗机构、病人和个人对胆固醇检测产品的需求增加。由于生活方式疾病、胆固醇监测意识的提高以及胆固醇检测产品的技术进步，市场预计将增长。

市场动态

生活方式疾病的发病率不断增加

生活方式疾病的日益盛行是推动胆固醇检测产品市场增长的主要因素之一。肥胖、糖尿病和高血压等生活方式疾病是高胆固醇水平和心血管疾病的已知风险因素。

例如，根据世界卫生组织的数据，非传染性疾病，包括心血管疾病、糖尿病和癌症，约占全球所有死亡的71%。不健康的生活习惯，如缺乏体力活动、不健康的饮食和吸烟，是这些疾病的关键风险因素。

随着这些生活方式疾病的发病率不断上升，对有效的预防、诊断和管理策略的需求也越来越大。胆固醇检测产品在早期检测和管理高胆固醇水平和心血管疾病方面发挥着关键作用。这增加了对胆固醇检测产品的需求，因为医疗保健提供者寻求解决日益增长的生活方式疾病的负担，并改善病人的结果。

产品的高成本和严格的监管要求

该市场的主要挑战是胆固醇检测产品的高成本和严格的监管要求。胆固醇检测产品的开发和商业化涉及大量的研究和开发成本，这可能导致最终产品的高价格。这可能会限制低收入国家和服务不足人群的获得，并限制新兴经济体的市场增长。

胆固醇检测产品的监管要求可能很严格，特别是在发达国家。这些要求包括上市前的批准，临床试验，以及遵守标准和法规。不遵守法规可能导致罚款和其他处罚，使中小型企业难以进入市场并与大型企业竞争。

COVID-19影响分析

COVID-19大流行病对胆固醇检测产品市场产生了影响。在大流行的早期阶段，医疗系统被COVID-19患者淹没，导致选择性手术的减少，包括常规胆固醇检测。然而，随着大流行病的持续和医疗系统适应新常态，对胆固醇检测产品的需求开始恢复。

此外，大流行病导致了远程医疗和远程监控的激增，这为胆固醇检测产品创造了新的机会。患者现在可以远程获得胆固醇检测产品，并接受医疗服务提供者的虚拟咨询，改善了获得护理的机会，减少了接触COVID-19的风险。

俄罗斯-乌克兰冲突分析

俄罗斯和乌克兰之间的冲突已经极大地影响了全球政治和经济格局，包括医疗保健行业。在乌克兰，竞争导致国内流离失所者的数量大幅增加，医疗设施和基础设施遭到破坏。

在俄罗斯，冲突导致了贸易限制和经济制裁，限制了医疗设备和用品的供应，破坏了供应链，使公司更难制造和分销医疗保健产品。这些限制限制了医疗设备和用品的供应，扰乱了供应链，使公司更难制造和分销保健产品。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按产品抽查
  • 按测试类型分类
  • 按终端用户分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 生活方式疾病发病率的提高
    • 限制因素
      • 产品的高成本和严格的监管要求
    • 机会
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • 后COVID-19或未来的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按产品分类

  • 设备
    • 手持式胆固醇监测设备
    • 台式胆固醇监测设备
    • 耗材
  • 测试套件
  • 其他

第8章：按测试类型

  • 总胆固醇
  • 低密度脂蛋白（LDL）胆固醇
  • 高密度脂蛋白(HDL)胆固醇
  • 甘油三酯
  • 极低密度脂蛋白（VLDL）胆固醇

第九章：按终端用户分类

  • 医院
  • 诊断中心
  • 家庭保健
  • 研究实验室

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • Abbott Laboratories
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • F. Hoffmann-La Roche AG
  • Siemens Healthineers
  • Danaher Corporation
  • Bio-Rad Laboratories Inc.
  • ACON Laboratories Inc.
  • Lepu Medical Technology
  • SD BIOSENSOR INC.
  • Ciga Healthcare
  • SpectraCell Laboratories Inc.

第十三章 ：附录

简介目录
Product Code: MD4219

Market Overview

The Global Cholesterol Testing Products Market size reached US$ 8.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 15.9 billion by 2030. The market is exhibiting at a CAGR of 8.3% during the forecast period 2023-2030.

Cholesterol testing products are medical devices, test kits, reagents, and consumables used to measure and monitor cholesterol levels in the blood. High cholesterol levels in the blood can increase the risk of cardiovascular diseases such as heart attack and stroke. Healthcare providers use these products to measure and monitor cholesterol levels in patients with or at risk of cardiovascular diseases.

The market for cholesterol testing products is driven by a growing awareness of the health risks associated with high cholesterol levels, such as cardiovascular disease, stroke, and diabetes. This has led to an increased demand for cholesterol testing products by healthcare providers, patients, and individuals. The market is expected to grow due to lifestyle diseases, increased awareness of cholesterol monitoring, and technological advancements in cholesterol testing products.

Market Dynamics

Increasing Prevalence of Lifestyle Diseases

The increasing prevalence of lifestyle diseases is one of the major factors driving the growth of the cholesterol-testing products market. Lifestyle diseases such as obesity, diabetes, and hypertension are known risk factors for high cholesterol levels and cardiovascular diseases.

For instance, According to the World Health Organization, noncommunicable diseases, including cardiovascular diseases, diabetes, and cancer, account for approximately 71% of all deaths globally. Unhealthy lifestyle habits such as lack of physical activity, unhealthy diets, and tobacco use are key risk factors for these diseases.

As the prevalence of these lifestyle diseases continues to rise, there is a growing need for effective prevention, diagnosis, and management strategies. Cholesterol testing products play a crucial role in detecting and managing high cholesterol levels and cardiovascular diseases early. This has increased the demand for cholesterol testing products as healthcare providers seek to address the growing burden of lifestyle diseases and improve patient outcomes.

High Cost of the Products and Stringent Regulatory Requirements

The market's major challenges are the high cost of cholesterol testing products and stringent regulatory requirements. The development and commercialization of cholesterol testing products involves significant research and development costs, which can lead to a high price of the final products. This can limit accessibility in low-income countries and underserved populations and restrict the market growth in emerging economies.

The regulatory requirements for cholesterol testing products can be stringent, particularly in developed countries. These requirements include pre-market approval, clinical trials, and compliance with standards and regulations. Failure to comply with regulations can result in fines and other penalties, making it difficult for small and medium-sized enterprises to enter the market and compete with larger players.

COVID-19 Impact Analysis

The COVID-19 pandemic has had an impact on the cholesterol testing products market. During the early stages of the pandemic, healthcare systems were overwhelmed with COVID-19 patients, leading to a decrease in elective procedures, including routine cholesterol testing. However, as the pandemic continued and healthcare systems adapted to the new normal, the demand for cholesterol testing products began to recover.

Additionally, the pandemic has led to a surge in telemedicine and remote monitoring, which has created new opportunities for cholesterol testing products. Patients can now access cholesterol testing products remotely and receive virtual consultations with healthcare providers, improving access to care and reducing the risk of exposure to COVID-19.

Russia-Ukraine Conflict Analysis

The conflict between Russia and Ukraine has significantly impacted the global political and economic landscape, including the healthcare industry. In Ukraine, the competition has caused a significant increase in the number of internally displaced persons and destroyed healthcare facilities and infrastructure.

In Russia, the conflict has led to trade restrictions and economic sanctions, which have limited the availability of medical equipment and supplies, and disrupted supply chains, making it more difficult for companies to manufacture and distribute healthcare products. These restrictions have limited the availability of medical equipment and supplies and disrupted supply chains, making it more difficult for companies to manufacture and distribute healthcare products.

Segment Analysis

The Global Cholesterol Testing Products Market is segmented based on product, test type, end-user, and region.

The devices segment is expected to dominate the market share based on product.

The devices segment accounted for the highest market stake, accounting for approximately 52.4% of the cholesterol testing products market in 2022 due to the increasing demand for reliable and accurate devices. These devices include handheld cholesterol testing devices, point-of-care testing devices, and home cholesterol testing kits. Additionally, the growing trend of self-monitoring of cholesterol levels has increased demand for home cholesterol testing kits.

The devices segment is expected to witness significant growth in the coming years due to technological advancements, increasing demand for point-of-care testing, and the rising prevalence of lifestyle diseases such as diabetes and obesity. The development of portable and wireless cholesterol testing devices is also expected to boost the growth of this segment.

Geographical Analysis

North America will capture the highest market share due to the increased prevalence of cardiovascular diseases and demand for POCT Products.

North America has a significant market share of around 39.6% for the cholesterol testing products market due to the increased prevalence of cardiovascular diseases and the growing demand for point-of-care testing (POCT) products. Cardiovascular diseases (CVDs) are a major public health concern in North America, and high cholesterol is a significant risk factor for developing CVDs. The increasing prevalence of CVDs in the region has led to a growing demand for cholesterol testing products, including laboratory-based and POCT devices.

Furthermore, the demand for POCT products is increasing in North America, driven by the need for rapid and accurate testing results, convenience, and cost-effectiveness. POCT devices allow cholesterol testing to be performed at the point of care, such as in a doctor's office or clinic, without requiring samples to be sent to a laboratory for analysis.

In addition, the region is home to several key players in the cholesterol testing products market, who are constantly introducing new and innovative products to meet the growing demand for cholesterol testing. These companies are also investing in research and development to improve the accuracy and reliability of cholesterol testing products.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories Inc., ACON Laboratories Inc., Lepu Medical Technology, SD BIOSENSOR INC., Ciga Healthcare, and SpectraCell Laboratories Inc.

Why Purchase the Report?

  • To visualize the Global Cholesterol Testing Products Market segmentation based on product, test type, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous cholesterol testing products market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Cholesterol Testing Products Market Report Would Provide Approximately 54 Tables, 46 Figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Prevalence of Lifestyle Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Products and Stringent Regulatory Requirements
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Handheld cholesterol monitoring devices
    • 7.2.4. Bench-top cholesterol monitoring devices
    • 7.2.5. Consumables
  • 7.3. Test Kits
  • 7.4. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type
  • 8.2. Total Cholesterol*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Low-Density Lipoprotein (LDL) Cholesterol
  • 8.4. High-Density Lipoprotein (HDL) Cholesterol
  • 8.5. Triglycerides
  • 8.6. Very Low-Density Lipoprotein (VLDL) Cholesterol

9. By End-User

  • 9.1. Hospitals
  • 9.2. Diagnostic centers
  • 9.3. Home healthcare
  • 9.4. Research laboratories

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. F. Hoffmann-La Roche AG
  • 12.3. Siemens Healthineers
  • 12.4. Danaher Corporation
  • 12.5. Bio-Rad Laboratories Inc.
  • 12.6. ACON Laboratories Inc.
  • 12.7. Lepu Medical Technology
  • 12.8. SD BIOSENSOR INC.
  • 12.9. Ciga Healthcare
  • 12.10. SpectraCell Laboratories Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us